/PRNewswire/ Totus Medicines, the drug discovery company mapping the universe of molecular drug interactions across the entire human genome to eliminate.
<ul>
<li>UK and NL-based VC firm Finch Capital’s Europe III will target the Series A and B current growth funding gap for companies that shape the future of Financial Technology</li>
<li>Investment focus: European category leaders with EUR 2-5M in revenues consolidating the fragmented Fintech landscape with a strong focus on those that leverage AI</li>
<li>In 2020, Google and DeepMind alum Steve Crossan joined as venture partner to build out the firm’s AI expertise; Finch Capital now sources 20% of qualified leads with its ML dealflow tool Flowrence</li>
<li>Capital raised from Institutional Investors and 15-20% from Family Offices from the US, Europe and Asia despite the COVID-19 crisis</li>
</ul>